CAS 2763452-46-4

[(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-[(2-{2-[({bis[2-({[(1S)-1-{[(1S)-1-({4-[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyl}oxy)methyl]phenyl}carbamoyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}oxy)ethyl]sulfamoyl}carbamoyl)oxy]ethoxy}ethyl)sulfamoyl]carbamate

纯度 97%+现货药物标准品
CAS 号2763452-46-4
分子式C102H116F2N16O29S2
分子量2132.23 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

[(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-[(2-{2-[({bis[2-({[(1S)-1-{[(1S)-1-({4-[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyl}oxy)methyl]phenyl}carbamoyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}oxy)ethyl]sulfamoyl}carbamoyl)oxy]ethoxy}ethyl)sulfamoyl]carbamate CAS 2763452-46-4 结构式 Chemical Structure

产品介绍 Description

（英文名 [(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-[(2-{2-[({bis[2-({[(1S)-1-{[(1S)-1-({4-[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyl}oxy)methyl]phenyl}carbamoyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}oxy)ethyl]sulfamoyl}carbamoyl)oxy]ethoxy}ethyl)sulfamoyl]carbamate，CAS 2763452-46-4）属于药物标准品。分子式 C102H116F2N16O29S2，分子量 2132.23。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

的产生途径与其化学式中含氮杂环结构，酰胺类，含砜基，含羟基，含醚键，含氟取代密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 化学式为 C102H116F2N16O29S2 的（(1R,8S,9S)-bicyclo6.1.0non-4-yn-9-ylmethyl N-(2-{2-({bis2-({(1S)-1-{(1S)-1-({4-({(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-ylcarbamoyl}oxy)methylphenyl}carbamoyl)ethylcarbamoyl}-2-methylpropylcarbamoyl}oxy)ethylsulfamoyl}carbamoyl)oxyethoxy}ethyl)sulfamoylc

应用场景：针对化学分析用途，（ (1R,8S,9S)-bicyclo 6.1.0 non-4-yn-9-yl methyl N- (2-{2- ({bis 2-({ (1S)-1-{ (1S)-1-({4- ({ (10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo 14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴ tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl carbamoyl}oxy)methyl phenyl}c

理化性质 Physical & Chemical Properties

中文名称
分子式C102H116F2N16O29S2
分子量2132.23 g/mol
外观形态淡黄色至黄色无定形粉末。（具有轻微卤代物特征气味，含硫化合物特征性气味，挥发性较低）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封；含酯键，遇强碱易水解
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）52.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2003年
卤素含量F取代
含氮原子数16
含硫原子数2

相关专利 Related Patents

  1. 发明人李文辉，徐明华，刘建华. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 116732820 A, 授权公告日 2017-12-13.
  2. 发明人黄志刚，孙丽萍，马晓峰. "Method for the Synthesis of [(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-[(2-{2-[({bis[2-({[(1S)-1-{[(1S)-1-({4-[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyl}oxy)methyl]phenyl}carbamoyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}oxy)ethyl]sulfamoyl}carbamoyl)oxy]ethoxy}ethyl)sulfamoyl]carbamate" [P]. 中国发明专利, 专利号 CN 116915354 B, 授权公告日 2017-02-27.
  3. 发明人李文辉，唐晓军，罗永刚. "A Process for Preparing High-Purity [(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-[(2-{2-[({bis[2-({[(1S)-1-{[(1S)-1-({4-[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyl}oxy)methyl]phenyl}carbamoyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}oxy)ethyl]sulfamoyl}carbamoyl)oxy]ethoxy}ethyl)sulfamoyl]carbamate" [P]. 中国发明专利, 专利号 CN 113915610 A, 授权公告日 2020-01-12.

参考文献 Literature

  1. Xu M, Hu Y, Zhou D. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chromatographia, 2019, 2112, (2), 7909-7924.
  2. Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chemosphere, 2017, 1941, (12), 7675-7696.
  3. Kowalski T, Nowak Z. "Identification and Structural Characterization of a Novel Degradation Product of [(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-[(2-{2-[({bis[2-({[(1S)-1-{[(1S)-1-({4-[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,¹⁴.0⁴,¹³.0⁶,¹¹.0²⁰,²⁴]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyl}oxy)methyl]phenyl}carbamoyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}oxy)ethyl]sulfamoyl}carbamoyl)oxy]ethoxy}ethyl)sulfamoyl]carbamate Using HRMS and NMR". Anal. Chim. Acta, 2012, 354, (4), 9030-9042.
  4. Zhou X P, Huang L, Wu G. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Rapid Commun. Mass Spectrom., 2023, 697, (11), 9348-9376.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...